Peroxisome proliferator-activated
receptor γ (PPARγ)
is a ligand-activated transcription factor that plays an important
role in adipogenesis and glucose metabolism. The ligand-binding pocket
(LBP) of PPARγ has a large Y-shaped cavity with multiple subpockets
where multiple ligands can simultaneously bind and cooperatively activate
PPARγ. Focusing on this unique property of the PPARγ LBP,
we describe a novel two-step cell-based strategy to develop PPARγ
ligands. First, a combination of ligands that cooperatively activates
PPARγ was identified using a luciferase reporter assay. Second,
hybrid ligands were designed and synthesized. For proof of concept,
we focused on covalent agonists, which activate PPARγ through
a unique activation mechanism regulated by a covalent linkage with
the Cys285 residue in the PPARγ LBP. Despite their biological
significance and pharmacological potential, few covalent PPARγ
agonists are known except for endogenous fatty acid metabolites. With
our strategy, we determined that plant-derived cinnamic acid derivatives
cooperatively activated PPARγ by combining with GW9662, an irreversible
antagonist. GW9662 covalently reacts with the Cys285 residue. A docking
study predicted that a cinnamic acid derivative can bind to the open
cavity in GW9662-bound PPARγ LBP. On the basis of the putative
binding mode, structures of both ligands were linked successfully
to create a potent PPARγ agonist, which enhanced the transactivation
potential of PPARγ at submicromolar levels through covalent
modification of Cys285. Our approach could lead to the discovery of
novel high-potency PPARγ agonists.